UroGen's Commercial Performance and Pipeline Expansion
On August 20, UroGen Pharma entered into an Option and Research License Agreement with IntraGel Therapeutics for up to $7 million in equity investment. The deal grants UroGen access to develop three oncology products using IntraGel's SRGel platform and provides the option to acquire TumoCure, a head and neck cancer therapy still in clinical development. UroGen’s core business is showing strong growth: ZUSDURI generated $50.4 million in revenue for Q2 2026, up from $29.1 million in Q1. The company reported increased adoption with 1,444 activated sites of care and a rise in repeat prescribers to 45%. Updated Phase 3 data showed durable response rates without maintenance therapy. The IntraGel deal expands UroGen’s pipeline but remains conditional on future development milestones. TumoCure's early results from eight patients are promising, though limited by the small sample size and lack of long-term efficacy evidence.
Tickers: $URGN
Topics: IntraGel Therapeutics partnership URGN UroGen ZUSDURI revenue growth